Latest News

March 21, 2013
UCSF has named a highly accomplished pharmacist and clinical scientist, B. Joseph Guglielmo, PharmD, a 34-year member of the UCSF faculty, to lead the nation’s premier School of Pharmacy.
December 17, 2012
Drugs and medical devices tend to appear more beneficial in scientific papers if they were manufactured by the company that sponsored the study, showing that who pays for the clinical trial has a direct impact on the reported outcome, according to a new analysis by researchers at UCSF and the Cochrane Collaboration.
December 06, 2012
The rate of cancer survival is expected to keep climbing in coming years largely thanks to research discoveries that are translating into new cancer drugs, which currently account for roughly 30 percent of the pharmaceutical dollar, the chief scientific officer at Bristol-Myers Squib recently said at a showcase event for the UCSF Helen Diller Family Comprehensive Cancer Center.
November 06, 2012
Hospitalized heart failure patients who received the drug, serelaxin, in a phase III clinical trial had fewer disease symptoms and as a group experienced 37 percent fewer deaths over six months, according to results of a new study.
September 04, 2012
Pharmaceutical companies now have a guide — the UCSF-FDA TransPortal — to pre-clinical studies they should conduct to identify potentially harmful interactions between existing and new drugs that depend on how the drugs move into and out of cells through protein portals known as transporters.
July 01, 2012
People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.
June 14, 2012
A new approach to drug design, pioneered by a group of researchers at UCSF and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.
June 11, 2012
A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause side effects, according to a paper appearing online this week in the journal Nature.
May 09, 2012
Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it, according to a researcher at UCSF.
May 04, 2012
Academic medical centers can play a larger role in drug development and testing, according to an FDA official, who says there is a need for better strategies to identify winners, minimize costs and reduce failures during drug development.

Pages